title: Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant.
authors.affiliation: Division of Haematology and Internal Medicine, Department of Clinical and Biological Science, University of Turin, Turin. Electronic address: carmen.fava@unito.it.
authors.forename: Carmen
authors.initials: C
authors.lastname: Fava
authors.forename: Giovanna
authors.initials: G
authors.lastname: Rege-Cambrin
authors.forename: Alessandro
authors.initials: A
authors.lastname: Busca
authors.forename: Enrico
authors.initials: E
authors.lastname: Gottardi
authors.forename: Filomena
authors.initials: F
authors.lastname: Daraio
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Saglio
mesh_terms: D000293:Adolescent; D000328:Adult; D003131:Combined Modality Therapy; D000069439:Dasatinib; D005260:Female; D006801:Humans; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D033581:Stem Cell Transplantation / Q000379:methods*; D013844:Thiazoles / Q000627:therapeutic use*; D014184:Transplantation, Homologous; D055815:Young Adult
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib
keywords: Complete molecular remission; Minimal residual disease; Molecular relapse; Ph+ acute lymphoblastic leukemia; Tyrosine kinase inhibitors